Key regions: Germany, United States, India, Japan, United Kingdom
The Anti-Rheumatic Drugs market in Americas has been growing steadily over the years, driven by various factors such as increasing prevalence of rheumatoid arthritis, rising geriatric population, and growing healthcare expenditure.
Customer preferences: Patients suffering from rheumatoid arthritis prefer Anti-Rheumatic Drugs as it helps in reducing inflammation and pain associated with the disease. The preference for biologic drugs is also increasing due to their high efficacy and targeted mechanism of action.
Trends in the market: The United States dominates the Anti-Rheumatic Drugs market in Americas, owing to the high prevalence of rheumatoid arthritis and the presence of major market players. However, the market is expected to grow at a faster rate in Latin America due to increasing awareness about the disease and improving healthcare infrastructure. The market is also witnessing a shift towards biosimilars due to their lower cost and increasing availability.
Local special circumstances: Brazil is the largest market for Anti-Rheumatic Drugs in Latin America, owing to its large population and high prevalence of rheumatoid arthritis. However, the market is highly regulated and the approval process for new drugs is lengthy, which can hinder market growth. In Mexico, the market is driven by the increasing geriatric population and rising healthcare expenditure.
Underlying macroeconomic factors: The Anti-Rheumatic Drugs market in Americas is influenced by various macroeconomic factors such as healthcare expenditure, government regulations, and patent expirations. The increasing healthcare expenditure in the region is driving market growth, while government regulations and patent expirations are affecting the market dynamics. The market is also witnessing a trend towards consolidation, with major players acquiring smaller companies to expand their product portfolio and market presence.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
